Doximity, Inc.
Here’s whether Doximity, Inc. (DOCS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.32% over 10 days); RSI 61 — healthy momentum range; 3-month momentum positive (+30.7%); rising volume confirms the move (2.07x 30d avg). Concerns: trading below the 200-day MA (long-term downtrend); weak 1-year return of -61.0%. Currently 67.6% off its 52-week high. Score: +2/7.
DOCS is trading below its 200-day MA ($31.34) — a key warning sign the longer-term trend is under pressure. An RSI of 61.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -61.0% compares to +20.4% for SPY (trailed the market by 81.3%). The current 67.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.